Q-omics provides the consensus-scored CES1P1 profile across patient tissues and cancer cell-line models. CES1P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CES1P1 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, CES1P1 RNA expression shows 7,163 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LGG, LUAD, and ESCA as cancer lineages where CES1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CES1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CES1P1 survival associations across molecular data types. CES1P1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CES1P1 RNA expression–survival associations across cancer types. High CES1P1 expression shows unfavorable associations in LGG, GBM and KIRC, but favorable associations in PAAD, THCA and BLCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CES1P1 RNA expression.
This table summarizes CES1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CES1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CES1P1 shows lower tumor expression in LUAD, BRCA, BLCA, THCA, CHOL and UCEC. The LUAD box plot shows higher CES1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.871, t-test p < 0.001).
This table shows molecular features associated with CES1P1 in patient tissues and cancer cell lines. In patient samples, CES1P1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CES1P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
